Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 686
- Registration Number
- NCT06459180
- Locations
- 🇦🇷
Sanatorio Allende - Cerro-Oncology ( Site 0106), Córdoba, Cordoba, Argentina
🇧🇷Centro de Hematologia e Oncologia ( Site 0203), Joinville, Santa Catarina, Brazil
🇧🇷Americas Centro de Oncologia Integrado ( Site 0202), Rio de Janeiro, Brazil
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 110
- Registration Number
- NCT06449209
- Locations
- 🇺🇸
Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists, Tallahassee, Florida, United States
🇺🇸Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 50
- Registration Number
- NCT06425419
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT06394492
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 540
- Registration Number
- NCT06203210
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 650
- Registration Number
- NCT06161025
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳Hubei Cancer Hospital, Wuhan, China
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 686
- Registration Number
- NCT06128837
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT05990738
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇫🇷INS Curie, Paris, France
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05874401
- Locations
- 🇧🇪
CHU de Liège, Liege, Belgium
🇧🇪Centre Hospitalier de l'Ardenne, Libramont, Belgium
🇵🇱Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.